Dobrava-Belgrade orthohantavirus
Dobrava-Belgrade orthohantavirus (DOBV) is a species of virus in the genus Orthohantavirus, family Hantaviridae. It is a single-stranded, enveloped, negative-sense RNA virus. DOBV is one of several hantaviruses that cause Hantavirus hemorrhagic fever with renal syndrome (HFRS), a severe and often fatal disease in humans.
Taxonomy[edit]
DOBV is a member of the Orthohantavirus genus, which is part of the Bunyavirales order. The Orthohantavirus genus also includes other hantaviruses that cause HFRS, such as Hantaan virus and Seoul virus.
Structure and Genome[edit]
Like all hantaviruses, DOBV is enveloped and has a single-stranded, negative-sense RNA genome. The genome is segmented into three parts: the S (small), M (medium), and L (large) segments. The S segment encodes the nucleocapsid protein, the M segment encodes the envelope glycoproteins Gn and Gc, and the L segment encodes the RNA-dependent RNA polymerase.
Transmission and Disease[edit]
DOBV is primarily transmitted to humans through inhalation of aerosolized virus particles from the feces, urine, or saliva of infected rodents, particularly the yellow-necked field mouse (Apodemus flavicollis) and the striped field mouse (Apodemus agrarius).
In humans, DOBV causes Hantavirus hemorrhagic fever with renal syndrome (HFRS), a severe disease characterized by fever, hemorrhage, and kidney failure. The fatality rate of HFRS caused by DOBV is approximately 5-10%.
Prevention and Control[edit]
Prevention of DOBV infection primarily involves avoiding contact with rodents and their droppings. This can be achieved through rodent control measures and by taking precautions when entering rodent-infested areas. There is currently no specific antiviral treatment for DOBV infection, and management of the disease is primarily supportive.
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian